Pfizer stock is up at $44.71 as of 10:49 AM EDT on Thursday.
As part of its COVID-19 Response Mechanism, Pfizer (NYSE:PFE) struck an agreement to provide up to 6 million treatment courses of its COVID-19 oral medication Paxlovid to the Global Fund (C19RM).
The 132 low- and middle-income nations that qualify for the Global Fund will be able to purchase the medication beginning this year, pending local regulatory permission or authorization, the company announced in a news statement on September 22.
According to Pfizer, C19RM has been the primary method for giving low- and middle-income countries grant funding to purchase COVID-19 tests, treatments, and personal protective equipment, among other things.
The company noted that all low- and lower-middle-income nations will pay a not-for-profit price, while upper-middle-income nations will pay the price stipulated by Pfizer’s tiered pricing strategy.
In March, Pfizer agreed to give UNICEF access to up to 4 million Paxlovid (nirmatrelvir/ritonavir pills) treatment courses for 95 low- and middle-income nations.
Pfizer Announces Q4 Dividend for 2022
Pfizer Inc. ( NYSE:PFE) issued a $0.40 dividend on the company’s common stock for the fourth quarter of 2022. The dividend is payable on December 5, 2022, to holders of record as of the close of business on November 4, 2022. The Q4 cash dividend of 2022 will mark Pfizer‘s 336th successive quarterly dividend payment.
Pfizer stock, Financials
Pfizer Inc. (NYSE:PFE) provided a webcast of a conference call with financial analysts for investors and the general public to observe and listen to. The call’s objective is to offer a status report on Pfizer stock’s performance as it will be detailed in the company’s Third Quarter 2022 Performance Report, which will be released that morning.
Featured Image- Megapixl @Michaelvi